Revised SPC: Cyramza 10 mg/ml concentrate for solution for infusion

SPC now notes cases of posterior reversible encephalopathy syndrome (PRES), including fatal cases, have been rarely reported in patients receiving ramucirumab, and that treatment should be discontinued in patients who experience PRES.

Source:

electronic Medicines compendium